Earnings Report /
Sri Lanka

Hemas Holdings: 1Q FY22 - Near-term headwinds, but growth story intact

  • Pharma distribution and hospitals recovery drive top line growth

  • Local H&PC business to remain the key Consumer earnings driver in FY22E

  • We revise our target price to LKR 104.00/share and maintain our BUY rating

Asia Securities
20 August 2021
Published by